Novo Nordisk A/S (NVO) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 1 and 1 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Jakob Rode, Head of Investor Relations. Please go ahead. Thank you. Hello, everyone, and welcome to this Normal Nordisk earnings call for the first half year of 2025. My name is Jakob Rode, and I'm the Head of Investor Relations at Normal Nordisk. And with me today, I have CEO of Novo Nordisk, Lars Frohgård Jørgensen, Executive Vice President, Product and Portfolio Strategy, Ludovic Helfgaard, Executive Vice President, US Operations, Dave Moore, Executive Vice President and Head of Development, Martin Holtz-Lange, Chief Financial Officer, Carsten von Knudsen, and finally, Executive Vice President, International Operations, as well as incoming CEO as of August 7th, Mike Duster. All speakers will be available for the Q&A session. Today's announcement and the slides for this call are available on our website, novenoids.com. Please note that the call is being webcasted live and the recording will be made available on our website as well. The call is scheduled to last one hour. Please turn to the next slide. The presentation is structured as outlined on slide two. Please note that all sales and operating profit growth statements will be at constant exchange rates unless otherwise specified. Next slide, please. We need to advise you that this call will contain forward-looking statements. These are subject to risk and uncertainty that could cause actual results to differ materially from expectations. For further information on the risk factors, please see the company announcement for the first six months of 2025, ...